JPMorgan Chase & Co. Purchases 238,222 Shares of Hologic, Inc. (NASDAQ:HOLX)

JPMorgan Chase & Co. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,358,945 shares of the medical equipment provider's stock after buying an additional 238,222 shares during the period. JPMorgan Chase & Co. owned approximately 0.60% of Hologic worth $110,700,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC purchased a new position in shares of Hologic during the third quarter worth about $25,000. Groupama Asset Managment grew its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new position in shares of Hologic in the 2nd quarter worth $37,000. First Horizon Advisors Inc. raised its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares in the last quarter. Finally, Cromwell Holdings LLC lifted its holdings in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on HOLX shares. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and reduced their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Needham & Company LLC restated a "buy" rating and issued a $90.00 target price on shares of Hologic in a research report on Thursday, December 19th. BNP Paribas raised Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of "Moderate Buy" and an average target price of $89.50.

Hologic Trading Down 0.5 %

Hologic stock traded down $0.35 during trading hours on Thursday, reaching $71.74. The stock had a trading volume of 1,164,029 shares, compared to its average volume of 1,874,570. The company has a fifty day simple moving average of $76.87 and a 200-day simple moving average of $78.43. Hologic, Inc. has a 52 week low of $70.36 and a 52 week high of $84.67. The stock has a market cap of $16.28 billion, a PE ratio of 21.54, a PEG ratio of 2.32 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $0.89 earnings per share. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.75% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.